Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure: Baseline Characteristics of Patients in the RESHAPE-HF2 Trial and Comparison to COAPT and MITRA-FR Trials

Чрескожная коррекция умеренно-тяжёлой или тяжёлой функциональной митральной регургитации у пациентов с симптоматической сердечной недостаточностью: исходные характеристики пациентов исследования RESHAPE-HF2 и сравнение с исследованиями COAPT и MITRA-FR
Gerd P Hasenfuss, Ulf Landmesser, Mark Colquhoun Petrie, Piotr P. Ponikowski, Gerasimos S Filippatos, Alec S. Vahanian, Marco Metra, Frank Thomas Ruschitzka, Roberto Ferrari, Fausto José Pinto, Malte Kelm, Tienush Rassaf, Marianna Adamo, Stefan D. Anker, Javed Butler, Zbigniew F. Kalarus, John G.F. Cleland, Aldo Pietro Maggioni, Finn Gustafsson, Andreas Michael Zeiher, Mahir Karakas, Mitja Lainščak, Ottavio Alfieri, Ulrich Schäfer, Tim Friede, Muhammad Shahzeb Khan, Paul Christian Schulze, Antoni Bayés‐Genís, Angelo Auricchio, Karl‐Heinz Kück, William T. Abraham, Ralph Stephan von Bardeleben, Wojciech Wojakowski, Krzysztof F. Zmudka, Wolfgang Schillinger, Evelyn Santiago‐Vacas, Friedrich Koehler, Wilhelm Haverkamp, Ilias Ninios, Vlasis N. Ninios, José Luis Zamorano, Monika Diek, Jutta Heinrich, Martin Geyer, Marius Placzek, Konstantinos S. Spargias, Alper Ö Öner, Nikolaos Mezilis, Efstratios K. Theofilogiannakos, Michael P. Chrissoheris, Panagiota Kourkoveli, Konstantinos G. Papadopoulos, Grzegorz A. Smolka, Krzysztof W. Reczuch, Tobias Friedrich Ruf, Michael Gross, Joern Tongers
2024-06-07

MitraClip deviceRESHAPE-HF2 trialfunctional mitral regurgitationsymptomatic heart failuretranscatheter mitral repair
ABSTRACT Aim The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials. Methods and results The RESHAPE-HF2 study is an investigator-initiated, prospective, randomized, multicentre trial including patients with symptomatic HF, a left ventricular ejection fraction (LVEF) between 20% and 50% with moderate-to-severe or severe FMR, for whom isolated mitral valve surgery was not recommended. Patients were randomized 1:1 to a strategy of delivering or withholding MitraClip. Of 506 patients randomized, the mean age of the patients was 70 ± 10 years, and 99 of them (20%) were women. The median EuroSCORE II was 5.3 (2.8–9.0) and median plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 2745 (1407–5385) pg/ml. Most patients were prescribed beta-blockers (96%), diuretics (96%), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (82%) and mineralocorticoid receptor antagonists (82%). The use of sodium–glucose cotransporter 2 inhibitors was rare (7%). Cardiac resynchronization therapy (CRT) devices had been previously implanted in 29% of patients. Mean LVEF, left ventricular end-diastolic volume and effective regurgitant orifice area (EROA) were 31 ± 8%, 211 ± 76 ml and 0.25 ± 0.08 cm2, respectively, whereas 44% of patients had mitral regurgitation severity of grade 4+. Compared to patients enrolled in COAPT and MITRA-FR, those enrolled in RESHAPE-HF2 were less likely to have mitral regurgitation grade 4+ and, on average, HAD lower EROA, and plasma NT-proBNP and higher estimated glomerular filtration rate, but otherwise had similar age, comorbidities, CRT therapy and LVEF. Conclusion Patients enrolled in RESHAPE-HF2 represent a third distinct population where MitraClip was tested in, that is one mainly comprising of patients with moderate-to-severe FMR instead of only severe FMR, as enrolled in the COAPT and MITRA-FR trials. The results of RESHAPE-HF2 will provide crucial insights regarding broader application of the transcatheter edge-to-edge repair procedure in clinical practice.
1
Compared with COAPT and MITRA-FR, RESHAPE-HF2 patients had less grade 4+ mitral regurgitation, lower average EROA and NT-proBNP, and higher estimated glomerular filtration rate.
2
Despite differences in mitral-regurgitation severity and several disease markers, RESHAPE-HF2 patients had broadly similar age, comorbidities, CRT use, and LVEF to COAPT and MITRA-FR participants.
3
Guideline-directed heart-failure therapy was common, but sodium–glucose cotransporter 2 inhibitor use was rare at 7%; 29% had previously received cardiac resynchronization therapy.
4
Participants had substantial disease burden: mean LVEF was 31%, median NT-proBNP was 2745 pg/ml, and median EuroSCORE II was 5.3.
5
RESHAPE-HF2 enrolled 506 patients with symptomatic heart failure, LVEF 20–50%, and moderate-to-severe or severe functional mitral regurgitation unsuitable for isolated mitral surgery.

Patients with symptomatic heart failure, left ventricular ejection fraction of 20–50%, and moderate-to-severe or severe functional mitral regurgitation enrolled in the RESHAPE-HF2 trial

Baseline clinical characteristics and comparison with patients enrolled in the COAPT and MITRA-FR trials

Publication Details
Publication Date
2024-06-07
Journal
Publisher
ISSN
Cited by
41
Access Type
Author Information
Authors
Gerd P Hasenfuss
Ulf Landmesser
Mark Colquhoun Petrie
Piotr P. Ponikowski
Gerasimos S Filippatos
Alec S. Vahanian
Marco Metra
Frank Thomas Ruschitzka
Roberto Ferrari
Fausto José Pinto
Malte Kelm
Tienush Rassaf
Marianna Adamo
Stefan D. Anker
Javed Butler
Zbigniew F. Kalarus
John G.F. Cleland
Aldo Pietro Maggioni
Finn Gustafsson
Andreas Michael Zeiher
Mahir Karakas
Mitja Lainščak
Ottavio Alfieri
Ulrich Schäfer
Tim Friede
Muhammad Shahzeb Khan
Paul Christian Schulze
Antoni Bayés‐Genís
Angelo Auricchio
Karl‐Heinz Kück
William T. Abraham
Ralph Stephan von Bardeleben
Wojciech Wojakowski
Krzysztof F. Zmudka
Wolfgang Schillinger
Evelyn Santiago‐Vacas
Friedrich Koehler
Wilhelm Haverkamp
Ilias Ninios
Vlasis N. Ninios
José Luis Zamorano
Monika Diek
Jutta Heinrich
Martin Geyer
Marius Placzek
Konstantinos S. Spargias
Alper Ö Öner
Nikolaos Mezilis
Efstratios K. Theofilogiannakos
Michael P. Chrissoheris
Panagiota Kourkoveli
Konstantinos G. Papadopoulos
Grzegorz A. Smolka
Krzysztof W. Reczuch
Tobias Friedrich Ruf
Michael Gross
Joern Tongers
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%